Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Iron Mountain Inc (IRM) Price & Performance

Citius Pharmaceuticals IncTrade
Iron Mountain IncTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Iron Mountain Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M), while Iron Mountain Inc trades at $124.1 (market cap $36.44B). The key difference: Iron Mountain Inc is far larger — about 1821.1× Citius Pharmaceuticals Inc's market cap, and Iron Mountain Inc pays a 2.82% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRIRM
Market Cap
$20.01M$36.44B
Sector
HealthReal Estate
52-Week High
$1.82$133.06
52-Week Low
$0.48$78.86
Enterprise Value
$16.23M$55.85B
Dividend Yield
2.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

Iron Mountain Inc

Iron Mountain (IRM) trades at $124.67, up 2.56% today, with a bearish technical signal but strong recent earnings beats. Revenue grew to $6.90B in 2025, though net margins compressed to 2.09%. The stock is supported by a 65% analyst buy rating and a $141.50 consensus target, with institutional interest highlighted by recent purchases. Key risks include high debt levels, with a debt-to-asset ratio of 79.04% in 2025.

Outlook remains mixed; robust data center growth and dividend yield near 2.8% offer upside, but elevated valuation (P/E 86.8) and persistent negative shareholder equity warrant caution. Earnings momentum from Q2 2026 beat provides near-term support, yet debt servicing and competitive pressures pose headwinds for sustained gains.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Iron Mountain Inc

Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business

Read more on IRM